2024
Kansy A, Ashry R, Mustafa A, Alfayomy A, Radsak M, Zeyn Y, Bros M, Sippl W, Krämer O (2024)Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. Mol. Oncol., doi:10.1002/1878-0261.13638 Link
Nugyen A, Mustafa A, Leydecker A, Halilovic M, Murr J, Butter F, Krämer O (2024) The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells. Cell Commun Signal, doi:10.1186/s12964-024-01597-8 Link
Alfayomy AM, Ashry R, Kansy AG, Sarnow A-C, Erdmann F, Schmidt M, Krämer OH and Sippl W (2024) Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.Eur J Med Chem, doi: 10.1016/j.ejmech.2024.116167 Link
2023
Gül D, Krämer OH and Reinhardt C (2023) Starving out brain tumors: a reprogrammed lysine catabolism serves as a novel target for glioblastoma treatment. Signal Transduct Target Ther, doi: 10.1038/s41392-023-01616-z Link
Zeyn Y, Hausmann K, Halilovic M, Beyer M, Ibrahim HS, Brenner W, Mahboobi S, Bros M, Sippl W and Krämer OH (2023) Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3. Leukemia, doi: 10.1038/s41375-023-02036-2 Link
Wirth M, Brenner W and Krämer OH (2023) Boosting T cell immunity against cytomegalovirus: a potential strategy combating human aging and age-related diseases. Signal Transduct Target Ther, doi:10.1038/s41392-023-01590-6 Link
Abdallah DI, de Araujo ED, Patel NH, Hasan LS, Moriggl R, Krämer OH and Gunning PT (2023) Medicinal chemistry advances in targeting class I histone deacetylases. Explor Target Anti-tumor Ther, doi: 10.37349/etat.2023.00166 Link
Fischer MA, Mustafa AHM, Hausmann K, Ashry R, Kansy AG, Liebl MC, Brachetti C, Piée-Staffa A, Zessin M, Ibrahim HS, Hofmann TG, Schutkowski M, Sippl W and Krämer OH (2023) Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells. J Adv Res, doi: 10.1016/j.jare.2023.07.005 Link
Ashry R, Mustafa AHM, Hausmann K, Linnebacher M, Strand S, Sippl W, Wirth M and Krämer OH (2023) NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor. Cancers (Basel), doi: 10.3390/cancers15143650 Link
Mustafa AHM and Krämer OH (2023) Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacol Rev, doi: 10.1124/pharmrev.122.000612 Link
2022
Schneeweis C, Diersch S, Hassan Z, Krauß L, Schneider C, Lucarelli D, Falcomatà C, Steiger K, Öllinger R, Krämer OH, Arlt A, Grade M, Schmidt-Supprian M, Hessmann E, Wirth M, Rad R, Reichert M, Saur D and Schneider G (2023) AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Cell Mol Life Sci, doi: 10.1007/s00018-022-04638-y Link
Gül D, Olf S, Hagemann J, Stauber RH and Krämer OH (2023) Cloning Strategy for HDAC1/HDAC2 Hybrid Protein Expression in Mammalian Cells. Pages 401–409 in: Methods in molecular biology (Clifton, N.J.), vol. 2589, doi: 10.1007/978-1-0716-2788-4_26 Link
Winkler R, Mägdefrau A-S, Piskor E-M, Kleemann M, Beyer M, Linke K, Hansen L, Schaffer A-M, Hoffmann ME, Poepsel S, Heyd F, Beli P, Möröy T, Mahboobi S, Krämer OH and Kosan C (2022) Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. Oncogene, doi: 10.1038/s41388-022-02450-3 Link
Marx C, Sonnemann J, Maddocks ODK, Marx-Blümel L, Beyer M, Hoelzer D, Thierbach R, Maletzki C, Linnebacher M, Heinzel T and Krämer OH (2022) Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer Metab, doi:10.1186/s40170-022-00286-9 Link
Al-Hassan MM, Ashry R and Kramer OH (2022) Monitoring Changes in Intracellular Reactive Oxygen Species Levels in Response to Histone Deacetylase Inhibitors. Pp 293–302 in: Methods in molecular biology (Clifton, N.J.), doi: 10.1007/978-1-0716-2788-4_22 Link
Beyer M and Krämer OH (2022) RNA interference protocol to silence oncogenic drivers in leukemia cell lines. STAR Protoc, doi: 10.1016/j.xpro.2022.101512 Link
Kramer OH, Diehl T and Roos WP (2022)Assessing the Effect of Histone Deacetylase Inhibitors on DNA Double-Strand Break Repair by Non-Homologous End Joining . Pp 293–302 in: Methods in molecular biology (Clifton, N.J.), doi: 10.1007/978-1-0716-2788-4_19 Link
Pons M, Conradi R, Brenner W and Kramer OH (2022) Human Platelet Lysate as Valid Cell Growth Additive to Assess Protein Acetylation. Pp 87–94 in: Methods in molecular biology (Clifton, N.J.), doi: 10.1007/978-1-0716-2788-4_6 Link
Kiweler N, Schwarz H, Nguyen A, Matschos S, Mullins C, Piée-Staffa A, Brachetti C, Roos WP, Schneider G, Linnebacher M, Brenner W and Krämer OH (2022) The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. Cell Biol Toxicol, doi: 10.1007/s10565-022-09731-3 Link
Krämer OH and Schneider G (2022) Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma. Clin Transl Med, doi: 10.1002/ctm2.858 Link
Mieland AO, Beyer M and Krämer OH (2022) AUTOTACs join the arena for targeted protein degradation. Arch Toxicol, doi: 10.1007/s00204-022-03312-3 Link
Zeyen P, Zeyn Y, Herp D, Mahmoudi F, Yesiloglu TZ, Erdmann F, Schmidt M, Robaa D, Romier C, Ridinger J, Herbst-Gervasoni CJ, Christianson DW, Oehme I, Jung M, Krämer OH and Sippl W (2022) Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. Eur J Med Chem, doi: 10.1016/j.ejmech.2022.114272 Link
Schneeweis C, Hassan Z, Ascherl K, Wirth M, Koutsouli S, Orben F, Krauß L, Schneider C, Öllinger R, Krämer OH, Rad R, Reichert M, Robles MS, Saur D and Schneider G (2022) Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Cancer Commun, doi: 10.1002/cac2.12280 Link
Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, Illendula A, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G and Wirth M (2022) NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci, doi: 10.1073/pnas.2105691119 Link
Lu L, Przybylla R, Shang Y, Dai M, Krohn M, Krämer OH, Mullins CS and Linnebacher M (2022) Microsatellite Status and IκBα Expression Levels Predict Sensitivity to Pharmaceutical Curcumin in Colorectal Cancer Cells. Cancers (Basel), doi: 10.3390/cancers14041032 Link
2021
Ibrahim HS, Abdelsalam M, Zeyn Y, Zessin M, Mustafa A-HM, Fischer MA, Zeyen P, Sun P, Bülbül EF, Vecchio A, Erdmann F, Schmidt M, Robaa D, Barinka C, Romier C, Schutkowski M, Krämer OH and Sippl W (2021) Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. Int J Mol Sci, doi: 10.3390/ijms23010369 Link
Krauß L, Urban BC, Hastreiter S, Schneider C, Wenzel P, Hassan Z, Wirth M, Lankes K, Terrasi A, Klement C, Cernilogar FM, Ollinger R, de Andrade Krätzig N, Engleitner T, Schmid RM, Steiger K, Rad R, Krämer OH, Reichert M, Schotta G, Saur D and Schneider G (2021) HDAC2 facilitates pancreatic cancer metastasis. Cancer Res, doi: 10.1158/0008-5472.CAN-20-3209 Link
Beyer M, Henninger SJ, Haehnel PS, Mustafa A-HM, Gurdal E, Schubert B, Christmann M, Sellmer A, Mahboobi S, Drube S, Sippl W, Kindler T and Krämer OH (2021) Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. Cell Chem Biol, doi: 10.1016/j.chembiol.2021.10.011 Link
Wachholz V, Mustafa A-HM, Zeyn Y, Henninger SJ, Beyer M, Dzulko M, Piée-Staffa A, Brachetti C, Haehnel PS, Sellmer A, Mahboobi S, Kindler T, Brenner W, Nikolova T and Krämer OH (2021) Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol, doi: 10.1007/s00204-021-03174-1 Link
Nguyen A, Dzulko M, Murr J, Yen Y, Schneider G and Krämer OH (2021) Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. Cells, doi: 10.3390/cells10102520 Link
Mustafa A-HM and Krämer OH (2021) Novel insight into mechanisms for ATR activation by chromatin structures. Arch Toxicol, doi: 10.1007/s00204-021-03133-w Link
Marx C, Sonnemann J, Beyer M, Maddocks ODK, Lilla S, Hauzenberger I, Piée‐Staffa A, Siniuk K, Nunna S, Marx‐Blümel L, Westermann M, Wagner T, Meyer FB, Thierbach R, Mullins CS, Kdimati S, Linnebacher M, Neri F, Heinzel T, Wang Z and Krämer OH (2021) Mechanistic insights into p53‐regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Mol Oncol, doi: 10.1002/1878-0261.13060 Link
Pons M, Zeyn Y, Zahn S, Mahendrarajah N, Page BDG, Gunning PT, Moriggl R, Brenner W, Butter F and Krämer OH (2021) Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers (Basel), doi: 10.3390/cancers13143464 Link
Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S, Herling M and Gunning PT (2021) Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. J Med Chem, doi: 10.1021/acs.jmedchem.1c00420 Link
Göder A, Ginter T, Heinzel T, Stroh S, Fahrer J, Henke A and Krämer OH (2021) STAT1 N-terminal domain discriminatively controls type I and type II IFN signaling. Cytokine, doi: 10.1016/j.cyto.2021.155552 Link
Hassan Z, Schneeweis C, Wirth M, Müller S, Geismann C, Neuß T, Steiger K, Krämer OH, Schmid RM, Rad R, Arlt A, Reichert M, Saur D and Schneider G (2021) Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas. Pancreatology, doi: 10.1016/j.pan.2021.03.012 Link
2020
Schmalohr BF, Mustafa AM, Krämer OH and Imhof D (2020) Structural Insights into the Interaction of Heme with Protein Tyrosine Kinase JAK2*. ChemBioChem, doi: 10.1002/cbic.202000730 Link
Lankes K, Hassan ZZ, Doffo MJ, Schneeweis C, Lier S, Öllinger R, Rad R, Krämer OH, Keller U, Saur D, Reichert M, Schneider G and Wirth M (2020) Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC. Mol Oncol, doi: 10.1002/1878-0261.12835 Link
Dzulko M, Pons M, Henke A, Schneider G and Krämer OH (2020) The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. Biochim Biophys Acta - Rev Cancer, doi: 10.1016/j.bbcan.2020.188453 Link
Sellmer A, Pilsl B, Beyer M, Pongratz H, Wirth L, Elz S, Dove S, Henninger SJ, Spiekermann K, Polzer H, Klaeger S, Kuster B, Böhmer FD, Fiebig H-H, Krämer OH and Mahboobi S (2020) A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.Eur J Med Chem, doi: 10.1016/j.ejmech.2020.112232 Link
Kiweler N, Wünsch D, Wirth M, Mahendrarajah N, Schneider G, Stauber RH, Brenner W, Butter F and Krämer OH (2020) Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. J Cancer Res Clin Oncol, doi: 10.1007/s00432-019-03118-4 Link
2019
Beyer M, Romanski A, Mustafa A-HM, Pons M, Büchler I, Vogel A, Pautz A, Sellmer A, Schneider G, Bug G and Krämer OH (2019) HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of ß-catenin, MYC, and WT1.Cancers (Basel), doi: 10.3390/cancers11101436 Link
Heinz KS, Rapp A, Casas-Delucchi CS, Lehmkuhl A, Romero-Fernández I, Sánchez A, Krämer OH, Marchal JA and Cardoso MC (2019) DNA replication dynamics of vole genome and its epigenetic regulation.Epigenetics Chromatin, doi: 10.1186/s13072-019-0262-0 Link
Guo H, Treude F, Krämer OH, Lüscher B and Hartkamp J (2019) PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. Sci Rep, doi: 10.1038/s41598-019-45209-9 Link